Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy
Immunological Reviews · 2024-01 · 321 (1) · 94-114
DOI: 10.1111/imr.13251 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Immunological Reviews, online erschienen am 07.08.2023. Verfasst von Yong Xi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China. Hauptthemen laut MEDLINE: Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 164 Literaturangaben. Gefördert von: Major Science and Technology Innovation in 2025 Projects of Ningbo, China, Ningbo Clinical Research Center for Thoracic & Breast Neoplasms, Ningbo Medical & Health Leading Academic Discipline Project.
Abstract (Originalsprache)
Immunogenic cell death (ICD) is a unique mode of cell death, which can release immunogenic damage‐associated molecular patterns (DAMPs) and tumor‐associated antigens to trigger long‐term protective antitumor immune responses. Thus, amplifying “eat me signal” during tumor ICD cascade is critical for cancer immunotherapy. Some therapies (radiotherapy, photodynamic therapy (PDT), photothermal therapy (PTT), etc.) and inducers (chemotherapeutic agents, etc.) have enabled to initiate and/or facilitate ICD and activate antitumor immune responses. Recently, nanostructure‐based drug delivery systems have been synthesized for inducing ICD through combining treatment of chemotherapeutic agents, photosensitizers for PDT, photothermal transformation agents for PTT, radiosensitizers for radiotherapy, etc., which can release loaded agents at an appropriate dosage in the designated place at the appropriate time, contributing to higher efficiency and lower toxicity. Also, immunotherapeutic agents in combination with nanostructure‐based drug delivery systems can produce synergetic antitumor effects, thus potentiating immunotherapy. Overall, our review outlines the emerging ICD inducers, and nanostructure drug delivery systems loading diverse agents to evoke ICD through chemoradiotherapy, PDT, and PTT or combining immunotherapeutic agents. Moreover, we discuss the prospects and challenges of harnessing ICD induction‐based immunotherapy, and highlight the significance of multidisciplinary and interprofessional collaboration to promote the optimal translation of this treatment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Ningbo Medical Center Lihuili Hospital, Ningbo University, Ningbo, China.
- Department of Thoracic Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, China.
- School of Medicine, Xiamen University, Xiamen, China.
- China Medical University, Shenyang, China.
ORCID-Profile: Xing Niu
Förderung
- Major Science and Technology Innovation in 2025 Projects of Ningbo, China
- Ningbo Clinical Research Center for Thoracic & Breast Neoplasms
- Ningbo Medical & Health Leading Academic Discipline Project
- Ningbo Natural Science Foundation
- Natural Science Foundation of Ningbo
Zitieren
APA
Xi, Y., Chen, L., Tang, J., Yu, B., Shen, W., & Niu, X. (2024). Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy. Immunological Reviews, 321(1), 94-114. https://doi.org/10.1111/imr.13251
Vancouver
Xi Y, Chen L, Tang J, Yu B, Shen W, Niu X. Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy. Immunological Reviews. 2024;321(1):94-114. doi:10.1111/imr.13251
BibTeX
@article{Xi2024,
author = {Xi, Yong and Chen, Lijie and Tang, Jian and Yu, Bentong and Shen, Weiyu and Niu, Xing},
title = {Amplifying “eat me signal” by immunogenic cell death for potentiating cancer immunotherapy},
journal = {Immunological Reviews},
year = {2024},
volume = {321},
number = {1},
pages = {94--114},
doi = {10.1111/imr.13251}
}
EUVIMED